Anavex life sciences announces encouraging preliminary biomarker results from ongoing phase 2 study of anavex®3-71 for the treatment of schizophrenia

Part a of the placebo-controlled phase 2 study has been completed anavex®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective eeg biomarkers of schizophrenia patients are currently being dosed in part b of the phase 2 study which will investigate a longer treatment duration new york, oct. 17, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) diseases, today announced encouraging preliminary electroencephalography (eeg) biomarker results from the part a of the ongoing placebo-controlled phase 2 clinical study of anavex®3-71 for the treatment of schizophrenia. part a of the phase 2 study anavex®3-71-sz-001 (nct06245213), was a multiple ascending dose study in 16 participants treated with either oral placebo, oral anavex®3-71 90 mg daily, or oral anavex®3-71 180 mg daily for 10 days.
AVXL Ratings Summary
AVXL Quant Ranking